Pulse Biosciences Inc
NASDAQ: PLSE · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
Updated 2026-06-04
Pulse Biosciences Inc (PLSE) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for PLSE.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
PLSE historical valuation range
Where current P/E sits in PLSE's own 5Y range.
PLSE intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
PLSE valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 2310.37x
Is PLSE overvalued in 2026?
Pulse Biosciences Inc (PLSE) currently trades at $19.08 per share with a market capitalization of $1,735,087,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 16/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
PLSE currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 2310.4x, the market is valuing the company primarily on its revenue rather than its earnings.
Our discounted cash flow model estimates PLSE's intrinsic value at $18.10 per share, against the current market price of $19.08. This implies a premium to fair value of -39.50%. The current price sits well above what projected cash flows justify, implying investors are paying for growth that has not yet materialized.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: PLSE appears richly valued on our framework, with a Smart Value Score of 16/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is PLSE overvalued?
PLSE scores 16/100 on our Smart Value Score (Grade F), a weak overall profile. On valuation specifically, the DCF puts intrinsic value below the current price, so the stock is expensive on cash flow today. The score reflects growth and quality carrying it, not a cheap entry point.
What is PLSE's fair value?
Our DCF model estimates PLSE's intrinsic value at $18.10 per share, versus the current price of $19.08, a margin of safety of -39.50%. Fair value is the present value of the cash flows we project the business to produce, so a price above it means the market is paying up for growth the model does not yet assume.
What P/E ratio does PLSE trade at?
PLSE does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is PLSE a buy based on valuation?
Our Smart Value rating for PLSE is Strong Sell, from a Smart Value Score of 16/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does PLSE's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on PLSE.
What is PLSE's Smart Value Score?
PLSE's Smart Value Score is 16/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.